PrimeC, a new combination treatment by NeuroSense Therapeutics to slow down or halt the progression of amyotrophic lateral sclerosis (ALS), has received orphan drug status from the U.S. Food and Drug Administration (FDA), and is being investigated in two recently-initiated clinical trials. The decision to…
A new artificial intelligence (AI) algorithm can accurately predict the severity and progression of neurodegenerative diseases, such as Alzheimer’s and Huntington’s, by analyzing gene expression data from blood samples, researchers say. As the progression of these diseases is unique in every patient, this diagnostic algorithm has significant…
Dosing of healthy volunteers has been completed in a Phase 1 clinical trial evaluating Neos Therapeutics‘ experimental therapy NT0502 for chronic sialorrhea (excessive drooling), a common problem in people with amyotrophic lateral sclerosis (ALS). The open-label study includes 30 healthy adults who were assigned randomly to take one of…
Get regular updates to your inbox.